ACAD
Income statement / Annual
Last year (2025), Acadia Pharmaceuticals Inc's total revenue was $1.07 B,
an increase of 11.87% from the previous year.
In 2025, Acadia Pharmaceuticals Inc's net income was $391.00 M.
See Acadia Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.07 B |
$957.80 M |
$726.44 M |
$517.24 M |
$484.15 M |
$441.76 M |
$339.08 M |
$223.81 M |
$124.90 M |
$17.33 M |
| Cost of Revenue |
$89.00 M
|
$81.84 M
|
$45.73 M
|
$10.17 M
|
$19.14 M
|
$20.55 M
|
$19.60 M
|
$18.33 M
|
$13.06 M
|
$4.41 M
|
| Gross Profit |
$982.51 M
|
$875.96 M
|
$680.71 M
|
$507.07 M
|
$465.00 M
|
$421.21 M
|
$319.48 M
|
$205.48 M
|
$111.84 M
|
$12.93 M
|
| Gross Profit Ratio |
0.92
|
0.91
|
0.94
|
0.98
|
0.96
|
0.95
|
0.94
|
0.92
|
0.9
|
0.75
|
| Research and Development Expenses |
$328.80 M
|
$303.25 M
|
$351.62 M
|
$361.58 M
|
$239.42 M
|
$319.13 M
|
$240.39 M
|
$187.16 M
|
$149.19 M
|
$99.28 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$393.07 M
|
$0.00
|
$396.03 M
|
$388.66 M
|
$325.64 M
|
$225.96 M
|
$239.46 M
|
$186.46 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$9.40 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$39.80 M
|
$15.60 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$548.89 M
|
$488.43 M
|
$402.47 M
|
$369.09 M
|
$396.03 M
|
$388.66 M
|
$325.64 M
|
$265.76 M
|
$255.06 M
|
$186.46 M
|
| Other Expenses |
$0.00
|
-$146.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.84 M
|
$3.98 M
|
$1.33 M
|
| Operating Expenses |
$877.70 M
|
$645.16 M
|
$754.09 M
|
$730.67 M
|
$635.44 M
|
$707.79 M
|
$566.02 M
|
$452.92 M
|
$404.25 M
|
$285.74 M
|
| Cost And Expenses |
$966.69 M
|
$727.00 M
|
$799.82 M
|
$740.83 M
|
$654.58 M
|
$728.34 M
|
$585.62 M
|
$471.25 M
|
$417.31 M
|
$290.15 M
|
| Interest Income |
$31.72 M
|
$25.46 M
|
$17.23 M
|
$6.61 M
|
$591.00 K
|
$6.61 M
|
$11.17 M
|
$5.35 M
|
$4.13 M
|
$2.76 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$15.88 M
|
$5.55 M
|
$2.03 M
|
$3.34 M
|
$2.93 M
|
$2.77 M
|
$3.01 M
|
$2.71 M
|
$1.83 M
|
| EBITDA |
$138.90 M |
$100.16 M |
-$67.83 M |
-$221.57 M |
-$167.10 M |
-$283.65 M |
-$243.78 M |
-$244.44 M |
-$289.70 M |
-$270.99 M |
| EBITDA Ratio |
0.13
|
0.1
|
-0.09
|
-0.43
|
-0.35
|
-0.64
|
-0.72
|
-1.09
|
-2.32
|
-15.64
|
| Operating Income Ratio |
0.1
|
0.24
|
-0.1
|
-0.43
|
-0.35
|
-0.65
|
-0.73
|
-1.11
|
-2.34
|
-15.74
|
| Total Other Income/Expenses Net |
$34.09 M
|
$27.28 M
|
$22.34 M
|
$10.15 M
|
$2.92 M
|
$5.61 M
|
$12.16 M
|
$3.51 M
|
$4.13 M
|
$2.76 M
|
| Income Before Tax |
$138.90 M
|
$258.08 M
|
-$51.04 M
|
-$213.44 M
|
-$167.52 M
|
-$280.97 M
|
-$234.38 M
|
-$243.94 M
|
-$288.28 M
|
-$270.05 M
|
| Income Before Tax Ratio |
0.13
|
0.27
|
-0.07
|
-0.41
|
-0.35
|
-0.64
|
-0.69
|
-1.09
|
-2.31
|
-15.58
|
| Income Tax Expense |
-$252.10 M
|
$31.62 M
|
$10.25 M
|
$2.53 M
|
$351.00 K
|
$611.00 K
|
$876.00 K
|
$1.26 M
|
$1.12 M
|
$1.34 M
|
| Net Income |
$391.00 M
|
$226.45 M
|
-$61.29 M
|
-$215.98 M
|
-$167.87 M
|
-$281.58 M
|
-$235.26 M
|
-$245.19 M
|
-$289.40 M
|
-$271.39 M
|
| Net Income Ratio |
0.36
|
0.24
|
-0.08
|
-0.42
|
-0.35
|
-0.64
|
-0.69
|
-1.1
|
-2.32
|
-15.66
|
| EPS |
2.32 |
1.37 |
-0.37 |
-1.34 |
-1.05 |
-1.79 |
-1.6 |
-1.94 |
-2.36 |
-2.34 |
| EPS Diluted |
2.29 |
1.36 |
-0.37 |
-1.34 |
-1.05 |
-1.79 |
-1.6 |
-1.94 |
-2.36 |
-2.34 |
| Weighted Average Shares Out |
$169.34 M
|
$165.72 M
|
$163.82 M
|
$161.68 M
|
$160.49 M
|
$157.33 M
|
$147.20 M
|
$126.58 M
|
$122.60 M
|
$115.86 M
|
| Weighted Average Shares Out Diluted |
$171.36 M
|
$166.36 M
|
$163.82 M
|
$161.68 M
|
$160.49 M
|
$157.33 M
|
$147.20 M
|
$126.58 M
|
$122.60 M
|
$115.86 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
